Detalhe da pesquisa
1.
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
Int J Cancer
; 150(5): 837-846, 2022 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34648657
2.
Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial.
Am Heart J
; 145(1): 179-86, 2003 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-12514672